China NMPA Drug Inspection - Gansu Lanyao Pharmaceutical Co., Ltd. - Moneywort

The Gansu Provincial Food and Drug Administration, operating under China's National Medical Products Administration framework, released an announcement on October 15, 2018, detailing the outcomes of targeted supervision and sampling inspections. These inspections specifically focused on traditional Chinese medicine (TCM) decoction pieces, which had previously shown high rates of non-compliance. The initiative identified 11 batches of products from several companies, including Gansu Guocao Pharmaceutical Co., Ltd., Shaanxi Kangchao Kangjian Pharmaceutical Co., Ltd., Anhui Yiyuan Pharmaceutical Co., Ltd., Pingliang Zhukang Traditional Chinese Medicine Pieces Co., Ltd., Gansu Xuanyuan Pharmaceutical Development Co., Ltd., Baoji Xiangyuan Traditional Chinese Medicine Slices Co., Ltd., Baoji Hanfang Pharmaceutical Co., Ltd., and Gansu Lanya Pharmaceutical Co., Ltd., that failed to meet quality standards. Key violations included deficiencies in content determination (e.g., for Cattail Pollen, Kudzu Root, Licorice), improper moisture content (Alum), and non-compliance with product properties or impurity limits (Lysimachia christinae, Typha Pollen). These assessments were conducted based on standards outlined in the Chinese Pharmacopoeia (2010 and 2015 Editions) and the Gansu Provincial Standard for Traditional Chinese Medicine 2009 Edition, all within the regulatory framework of the "Drug Administration Law of the People's Republic of China." Required actions included immediate control measures like seizing and sealing non-compliant products, mandating enterprises to suspend sales and usage, and initiate rectification. Furthermore, local food and drug administrations were instructed to conduct thorough investigations into illegal activities and publicly disclose the findings for involved companies within three months to enhance drug quality and public safety.